secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTELLIGENT BIO SOLUTIONS INC. (INBS)
CIK:        0001725430
Form:       8-K
Filed at:   2026-02-12T23:59:59+00:00
Accession:  0001493152-26-006317
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Intelligent Bio Solutions Q2 revenue $896,774, up 48% YoY; reader sales surge 104%
--------------------------------------------------------------------------------

- Q2 total revenue $896,774, up 48% YoY; reader sales $246,519 (+104%), cartridge sales $516,754 (+33%).
- First-half FY2026 revenue $2.01M (+36% YoY); gross margin improved to 49% from 39%.
- Closed $10M private placement (net $9.4M received Jan 2, 2026) for working capital and FDA 510(k) submission.
- Initiated additional clinical studies for FDA 510(k); plans for U.S. market entry.
- Strategic alliance with Vlepis Pty Ltd for consumer health monitoring; major industrial service contract.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1725430/000149315226006317/0001493152-26-006317-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1725430/000149315226006317/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-006317

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer